Stay updated on Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.

Latest updates to the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page
- CheckyesterdayChange DetectedA new revision entry v3.6.5 with dates 2026-08-04, 2026-08-03, 2026-08 and 2027-07 was added, and the previous revision block v3.6.4 was removed. This reflects metadata or versioning updates rather than substantive changes to study information.SummaryDifference0.3%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4. This signals a new version of the page content and metadata.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedThe revision label changed from v3.6.2 to v3.6.3, indicating a minor version update in the page’s revision history.SummaryDifference0.0%

- Check44 days agoChange DetectedA new revision entry (v3.6.2) was added to the page history, replacing the previous v3.6.0 entry. This indicates a version update to the study page, potentially reflecting small textual or formatting adjustments.SummaryDifference0.0%

- Check58 days agoChange DetectedNew navigation/help links were added to assist users in joining and understanding the study: Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, and How to Join a Study. The Interventions header was reformatted from 'Intervention / Treatment' to 'Intervention/Treatment', and the page revision label was updated to v3.6.0.SummaryDifference0.4%

- Check65 days agoChange DetectedThe page's revision label was updated from v3.5.4 to v3.5.5. This indicates a small site update with no changes to the study details.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.